New cocktail of chemo and precision radiation aims to tame pancreatic cancer

NCT ID NCT04570943

Recruiting now Disease control Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a two-step approach for people with locally advanced pancreatic cancer that cannot be removed by surgery. First, patients receive two powerful chemotherapy regimens in sequence (GEMBRAX then FOLFIRINOX). Then, those whose cancer does not worsen get MRI-guided stereotactic radiotherapy, which delivers high-dose radiation very precisely. The goal is to stop the cancer from growing and to see if this combined treatment is safe and feasible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gemcitabine, nab-paclitaxel, oxaliplatin, leucovorin, irinotecan, 5-fluorouracil, and MRI-guided stereotactic radiotherapy
What this could lead to: If successful, this could offer a new treatment sequence to control locally advanced pancreatic cancer and potentially make it surgically removable.
What could go wrong: This is a mid-stage trial with only 103 participants, so results may not apply broadly. Chemotherapy and radiotherapy have significant side effects, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

CHU Carémeau
RECRUITING

Nîmes, Gard, 30029, France
CHU Saint-Eloi
RECRUITING

Montpellier, Herault, 34295, France
Centre Eugène Marquis
NOT_YET_RECRUITING

Rennes, 35042, France
Centre Georges-François Leclerc
RECRUITING

Dijon, 21079, France
Hopital Paul Brousse
NOT_YET_RECRUITING

Villejuif, France
Hôpital Beaujon
NOT_YET_RECRUITING

Clichy, France
Hôpital Pitié Salpétriêre
RECRUITING

Paris, 75013, France
Institut Paoli Calmettes
RECRUITING

Marseille, Bouches-du-Rhône, 13009, France
Institut régional du Cancer de Montpellier
RECRUITING

Montpellier, Hérault, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.